investors

Press Releases

DateTitle and SummaryView
November 17, 2017
LOS ANGELES , Nov. 17, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results on Tuesday, November 21, 2017 . The Company also plans to hold a conference call and webcast on that day
ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017
October 3, 2017
Live presentation will take place on October 11, 2017 at 2:00pm ET / 11:00am PT; Replay available on demand
ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET
September 13, 2017
LOS ANGELES , Sept. 13, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd.  (" ImmunoCellular " or the "Company") (NYSE MKT: IMUC) today announced that the NYSE MKT LLC (the "NYSE MKT") has accepted the Company's plan to regain compliance with the exchange's continued listing standards set
ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance
August 23, 2017
- Near-Term Milestones Anticipated in Stem-to-T-Cell Research Program -
- Restructuring Underway Designed to Achieve Cost Savings and Extend Operating Runway -
- Conference Call and Webcast Today at 5:00 pm ET -
ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy
August 14, 2017
-Company to Host Business Update Conference Call and Webcast on August 23, 2017-
ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results
July 18, 2017
LOS ANGELES , July 18, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd.  (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 5,000 shares of its Series B 8% Mandatorily Convertible Preferred Stock ("Preferred Stock") and related warrants
ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants
June 29, 2017
LOS ANGELES , June 29, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has received notification from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders'
ImmunoCellular Therapeutics Receives Notice from NYSE MKT for Noncompliance with Continued Listing Standards
June 21, 2017
LOS ANGELES , June 21, 2017 /PRNewswire/ --- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with
ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial
June 12, 2017
LOS ANGELES , June 12, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Anthony J. Gringeri , PhD, President and Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Marcum MicroCap
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017
June 5, 2017
ICT-121 Survival Data Encouraging
ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved